At a glance
ClinicalIndex Comparison Record- ✓Postmenopausal women at least 2 years past menopause
- ✓Osteopenia defined as T-score between -1.0 and -2.5 at lumbar spine or total hip
- ✓No prior fragility fractures
- ✕Renal insufficiency
- ✕Use of potassium-sparing diuretics
- ✕Use of potassium supplements
- ✕Hyperkalemia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia
In Brief
A Phase 4 clinical trial evaluating potassium citrate for Bone Diseases, Metabolic and Osteoporosis, Postmenopausal. Completed, enrolled 83 participants across 1 site.
Detailed Summary
Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss over time. Evidence from a few small short-term studies suggests that basic compounds, namely potassium citrate and potassium bicarbonate may reduce bone loss and improve bone density. The purpose of this study is to evaluate the effects of potassium citrate on bone metabolism. We hypothesize that administration of potassium citrate to postmenopausal women with osteopenia will reduce bone resorption and improve bone mineral density. Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of fracture will be randomized to either daily potassium citrate or placebo for one year. Primary outcomes will be markers of bone turnover, which will be measured over 12 months. Secondary outcomes will be bone mineral density, compliance, and adverse events.
Study Details
Timeline
Interventions
20 meq by mouth in capsule form twice daily